Anaptysbio, Inc (ANAB)
Anaptysbio, Inc (ANAB) is a Healthcare stock tracked by StreetAlpha. It last closed at $51.31 on Jul 20. ANAB reports earnings on Tue, Nov 3, 2026. The average 12-month price target from 3 analysts is $70.33 (+37.1% from the last close), with a high of $81.00 and a low of $60.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in ANAB, 100% of them bullish and 0% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on ANAB in the past 90 days. The average target is $70.33, with a high of $81.00 and a low of $60.00, compared with the last close of $51.31.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 30 | JP Morgan | Maintained | Buy | $60 |
| Sep 23 | Leerink Partners | Maintained | Buy | $81 |
| Aug 25 | TD Cowen | Maintained | Buy | $70 |
| Jun 10 | HC Wainwright & Co. | Assumed coverage | Buy | $95 |
Whale Options Flow
90DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANAB is in one of them and how their past ANAB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ANAB in an article yet. Here's the latest on the wider market.